Lucis Raises €17.1M to Scale Preventive Health AI

The big picture: Lucis, a Paris-based preventive health platform, secured €17.1 million ($20 million) in Series A funding. The round was led by Singular, with participation from General Catalyst, Y Combinator, and angel investors including Céline Lazorthes and Manu Lecomte. This brings Lucis’s total funding to €24 million ($28 million).

Why it matters:

• Addressing Late Diagnosis: Lucis aims to shift healthcare from reactive treatment to proactive prevention by using AI and biomarker analysis to identify potential health risks before symptoms manifest.
• Personalized Health Management: The platform offers tailored recommendations on nutrition, supplements, and lifestyle, empowering individuals to take data-driven control of their health.
• Demonstrated Efficacy: Early data from over 10,000 users shows 75% improved at least three biomarkers without medication within six months, with 80% opting for retesting, indicating sustained engagement and positive outcomes.

How it works:

• Comprehensive Biomarker Analysis: Lucis analyzes over 110 blood biomarkers across key health systems, including metabolic health, hormones, cardiovascular risk, inflammation, and nutrient levels.
• AI-Driven Health Companion: Results are integrated into an AI-powered app that uses longitudinal data and medical context to provide continuously refined, personalized advice.
• Clinical Oversight: All recommendations are reviewed by physicians, ensuring clinical safety and helping users understand and act on their health data effectively.

The catch: The preventive health market is competitive, with numerous apps and services vying for user attention. Lucis must continuously demonstrate superior clinical outcomes and maintain user engagement to differentiate itself. Navigating varying healthcare regulations and data privacy standards across European expansion markets will also present a significant challenge.